Treatment of anxiety disorders with venlafaxine XR

References

• Robins L, Helzer J, Weissman M et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch. Gen. Psychiatry 41, 949–958 (1984).
   PubMed Web of Science ®Google Scholar
• Kessler R, McGonagle K, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-r psychiatric disorders in the united states. Results from the national comorbidity survey. Arch. Gen. Psychiatry 51, 8–19 (1994).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, Jin R, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 93–602 (2005).
   Google Scholar
• Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 617–627 (2005).
   PubMed Web of Science ®Google Scholar
• Melartin T, Rytsala H, Leskela U, Lestela-Mielonen P, Sokero T, Isometsa E. Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa depression study. J. Clin. Psychiatry 63, 126–134 (2002).
   PubMed Web of Science ®Google Scholar
• Greenberg P, Sisitsky T, Kessler R et al. The economic burden of anxiety disorders in the 1990s. J. Clin. Psychiatry 60, 427–435 (1999).
   PubMed Web of Science ®Google Scholar
• DuPont R, DuPont C, Rice D. Economic costs of anxiety disorders. In: Textbook of Anxiety Disorders. Stein D, Hollander E (Eds), American Psychiatric Publishing, DC, USA 475–483, (2002).
   Google Scholar
• Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Undertreatment of Anxiety Disorders. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 629–640 (2005).
   PubMed Web of Science ®Google Scholar
• Ballenger J, Davidson J, Lecrubier Y et al. Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety. J. Clin. Psychiatry 62(Suppl. 11), 53–58 (2001).
   PubMed Web of Science ®Google Scholar
• Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J. Clin. Psychiatry 63(Suppl. 14), 9–16 (2002).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. Am. J. Psychiatry 155(Suppl. 5), 1–34 (1998).
   Web of Science ®Google Scholar
• The Expert Consensus Panel for obsessive-compulsive disorder. Treatment of obsessive-compulsive disorder. J. Clin. Psychiatry 58(Suppl. 4), 2–72 (1997).
   PubMedGoogle Scholar
• Ursano RJ, Bell C, Eth S et al. Practice guideline for the treatment of patients with acute stress disorder and post-traumatic stress disorder. Am. J. Psychiatry 161(Suppl. 11), 3–31 (2004).
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychopharmacol. 23, 250–259 (2003).
   PubMedGoogle Scholar
• Pecknold JC. A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Drug Saf. 16, 118–132 (1997).
   PubMedGoogle Scholar
• Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 9, 97–140 (2003).
   PubMedGoogle Scholar
• Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 35, 4493–4497 (1986).
   PubMed Web of Science ®Google Scholar
• Thase ME, Sloan DME. Venlafaxine. In: Textbook of Psychopharmacology Third Edition, Schatzberg AF, Nemeroff CB (Eds.), American Psychiatric Publishing Inc., DC, USA, 349–360 (2003).
   Google Scholar
• Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol. Psychiatry 55, 320–322 (2004).
   PubMed Web of Science ®Google Scholar
• Stahl SM. Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J. Clin. Psychiatry 59(Suppl. 4), 5–14 (1998).
   PubMed Web of Science ®Google Scholar
• Beique J, de Montigny C, Blier P, Debonnel G. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat. Neuropharmacology 24, 1800–1812 (2000).
   Google Scholar
• Roseboom PH, Kalin NH. Neuropharmacology of venlafaxine. Depress. Anxiety 12(Suppl. 1), 20–29 (2000).
   PubMed Web of Science ®Google Scholar
• Baron BM, Ogden AM, Siegel BW, Stegeman J, Ursillo RC, Dudley MW. Rapid down regulation of β-adrenoceptors by co-administration of desipramine and fluoxetine. Eur. J. Pharmacol. 154, 125–134 (1988).
   PubMed Web of Science ®Google Scholar
• Bitsios P, Szabadi E, Bradshaw CM. Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. J. Clin. Psychiatry 59, 502–508 (1998).
   PubMedGoogle Scholar
• Abdelmawla AH, Langley RW, Szabadi E, Bradshaw CM. Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Br. J. Clin. Pharmacol. 48, 345–354 (1999).
   PubMed Web of Science ®Google Scholar
• Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch. Gen. Psychiatry 57, 503–509 (2000).
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress. Anxiety. 12(Suppl. 1), 30–44 (2000).
   PubMed Web of Science ®Google Scholar
• Ball S, Ahern D, Scatina J, Kao J. Venlafaxine: In vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br. J. Clin. Pharmacol. 43, 619–626 (1997).
   PubMed Web of Science ®Google Scholar
• Gitlin M. Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome. J. Clin. Psychopharmacol. 17, 66–67 (1997).
   PubMedGoogle Scholar
• Davidson J, Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress. Anxiety 16(1), 4–13 (2002).
   PubMed Web of Science ®Google Scholar
• Silverstone P, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 study group. J. Clin. Psychiatry 60, 22–28 (1999).
   PubMed Web of Science ®Google Scholar
• Gorman JM, Papp LA. Efficacy of venlafaxine in mixed depression-anxiety states. Depress. Anxiety. 12(Suppl. 1), 30–44 (2000).
   Google Scholar
• Rudolph RL, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J. Affect. Disord. 47, 55–62 (1998).
   PubMedGoogle Scholar
• De Nayer A, Geerts S, Ruelens L et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int. J. Neuropsychopharmacol. 5, 115–120 (2002).
   PubMed Web of Science ®Google Scholar
• Silverstone P, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J. Clin. Psychiatry 62, 523–529 (2001).
   PubMed Web of Science ®Google Scholar
• Davidson J, Du Pont R, Hedges D, Haskins J. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J. Clin. Psychiatry 60, 528–535 (1999).
   PubMed Web of Science ®Google Scholar
• Hackett D, Haudiquet V, Salinas E. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur. Psychiatry 18, 182–187 (2003).
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack M, Sheehan D, Haskins J. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am. J. Psychiatry 157, 968–974 (2000).
   PubMed Web of Science ®Google Scholar
• Gelenberg A, Lydiard R, Rudolph R, Aguiar L, Haskins J, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283, 3082–3088 (2000).
   PubMed Web of Science ®Google Scholar
• Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (er) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br. J. Psychiatry 179, 15–22 (2001).
   PubMed Web of Science ®Google Scholar
• Montgomery S, Sheehan D, Meoni P, Haudiquet V, Hackett D. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J. Psychiatr. Res. 36, 209–217 (2002).
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Mahe V, Haudiquet V, Hackett D. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis. J. Clin. Psychopharmacol. 22, 561–567 (2002).
   PubMed Web of Science ®Google Scholar
• Katz IR, Reynolds CF 3rd, Alexopoulos GS, Hackett D. Venlafaxine XR as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J. Am. Geriatr. Soc. 50, 18–25 (2002).
   PubMed Web of Science ®Google Scholar
• Lenox-Smith AJ, Reynolds A. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br. J. Gen. Pract. 53, 772–777 (2003).
   PubMed Web of Science ®Google Scholar
• Nimatoudis I, Zissis NP, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int. Clin. Psychopharmacol. 19, 331–336 (2004).
   PubMed Web of Science ®Google Scholar
• Muller JE, Koen L, Seedat S, Stein DJ. Social anxiety disorder: current treatment recommendations. CNS Drugs 19, 377–391 (2005).
   PubMedGoogle Scholar
• Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine XR in adult outpatients with generalized social anxiety disorder. J. Clin. Psychopharmacol. 24, 488–496 (2004).
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Mangano RM, Bradwejn J, Asnis G. SAD Study Group. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J. Clin. Psychiatry 66, 238–247 (2005).
   PubMed Web of Science ®Google Scholar
• Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Br. J. Psychiatry 185, 37–45 (2004).
   PubMedGoogle Scholar
• Allgulander C, Mangano R, Zhang J et al. Efficacy of venlafaxine XR in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum. Psychopharmacol. 19, 387–396 (2004).
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch. Gen. Psychiatry 62, 190–198 (2005).
   PubMed Web of Science ®Google Scholar
• Mallick R, Mangano R, Shrivastava R. Improvement in functionality with treatment of generalized social anxiety disorder: Venlafaxine XR vs placebo. Eur. Neuropsychopharmacol. 12(Suppl. 3), S356 (2002).
   Google Scholar
• Rynn M, March J, Tourian K, Mangano R. Safety and efficacy of venlafaxine XR in the treatment of pediatric social anxiety disorder. Eur. Neuropsychopharmacol. 14(Suppl. 3), S306 (2004).
   Google Scholar
• Pollack MH, Worthington JJ 3rd, Otto MW et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol. Bull. 32, 667–670 (1996).
   PubMed Web of Science ®Google Scholar
• Bradwejn J, Emilien G, Whitaker T. Treatment of panic disorder with venlafaxine XR. Br. J. Psychiatry 187, 352–359 (2005).
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Asnis G, Tzanis E, Whitaker T. A double blind placebo controlled trial of venlafaxine XR in the short-term treatment of panic disorder. Eur. Neuropsychopharmacol. 14(Suppl. 3), S305–S306 (2004).
   Google Scholar
• Pollack M, Lepola U, Emilien G, Tzanis E, Whitaker T. Venlafaxine XR and paroxetine in the short-term treatment of panic disorder. Eur. Neuropsychopharmacol. 13(Suppl. 4), S378 (2003).
   Google Scholar
• Pollack M, Whitaker T, Mangano R, Tazanis E. A comparison of venlafaxine XR and paroxetine in the treatment of outpatients with panic disorder. Poster presented at the Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 12–16, (2004).
   Google Scholar
• Ferguson J, Whitaker T, Mangano R, Tzanis E. Preventing relapse of panic disorder in adult outpatient responders to venlafaxine XR. Poster presented at the Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 12–16, (2004).
   Google Scholar
• Davidson J, Lipschitz A, Musgnung J. Venlafaxine XR and sertraline in PTSD: a placebo-controlled study. Eur. Neuropsychopharmacol. 13(Suppl. 4), S380 (2003).
   Google Scholar
• Davidson J, Baldwin D, Stein DJ et al. Treatment of postratumatic stress disorder with venlafaxine XR: A 6-month randomized controlled trial. Poster presented at the Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 12–16, (2004).
   Google Scholar
• Schwartz AC, Rothbaum BO. Review of sertraline in post-traumatic stress disorder. Expert Opin. Pharmacother. 3, 1489–1499 (2002).
   PubMedGoogle Scholar
• Albert U, Aguglia E, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J. Clin. Psychiatry 63, 1004–1009 (2002).
   PubMed Web of Science ®Google Scholar
• Denys D, van der Wee N, van Megen HJ, Westenberg HG. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J. Clin. Psychopharmacol. 23, 568–575 (2003).
   PubMed Web of Science ®Google Scholar
• Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J. Clin. Psychiatry 65, 37–43 (2004).
   PubMed Web of Science ®Google Scholar
• Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 325(7376), 1332–1333 (2002).
   PubMed Web of Science ®Google Scholar
• Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 96, 369–374 (2003).
   PubMed Web of Science ®Google Scholar
• Mines D, Hill D, Yu H, Novelli L Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol. Drug Saf. 14, 367–372 (2005).
   PubMed Web of Science ®Google Scholar
• Mackay FR, Dunn NR, Martin RM, Pearce GL, Freemantle SN, Mann RD. Newer antidepressants: a comparison of tolerability in general practice. Br. J. Gen. Pract. 49(448), 892–896 (1999).
   PubMedGoogle Scholar
• Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can. J. Psychiatry 47, 174–180 (2002).
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J. Clin. Psychiatry 61, 276–281 (2000).
   PubMed Web of Science ®Google Scholar
• Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry 62(Suppl. 3), 10–21 (2001).
   PubMed Web of Science ®Google Scholar
• Clayton AH, Pradko JF, Croft HA et al. Prevalence of sexual dysfunction among newer antidepressants. J. Clin. Psychiatry 63, 357–366 (2002).
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation symptoms in depression and anxiety disorders. Int. J. Neuropsychopharmacol. 19, 1–12 (2005).
   Google Scholar
• Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J. Clin. Psychiatry 59, 502–508 (1998).
   PubMed Web of Science ®Google Scholar
• Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J. Clin. Psychiatry 56, 574–579 (1995).
   PubMedGoogle Scholar
• Montgomery SA, Entsuah R, Hackett D, Kunz NR, Rudolph RL. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J. Clin. Psychiatry 65, 328–336 (2004).
   PubMed Web of Science ®Google Scholar
• Simon JS, Aguier LM, Kunz NR, Lei D. Extended release venlafaxine in relapse prevention for patients with major depressive disorder. J. Psychiatric Research 38, 249–257 (2004).
   Google Scholar
• Schlienger RG, Fischer LM, Jick H, Meier CR. Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf. 27, 1157–1165 (2004).
   PubMed Web of Science ®Google Scholar
• Post RM, Altshuler LL, Frye MA et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord. 3, 259–265 (2001).
   PubMed Web of Science ®Google Scholar
• Vieta E, Martinez-Aran A, Goikolea JM et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J. Clin. Psychiatry 63, 508–512 (2002).
   PubMed Web of Science ®Google Scholar
• Simon NM, Otto MW, Wisniewski SR et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am. J. Psychiatry 161, 2222–2229 (2004).
   PubMed Web of Science ®Google Scholar
• Murray ML, Thompson M, Santosh PJ, Wong IC. Effects of the Committee on Safety of Medicines Advice on Antidepressant Prescribing to Children and Adolescents in the UK. Drug Saf. 28, 1151–1157 (2005).
   PubMed Web of Science ®Google Scholar
• Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363, 1341–1345 (2004).
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178, 234–241 (2001).
   PubMed Web of Science ®Google Scholar
• Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br. J. Psychiatry. 180, 396–404 (2002).
   PubMed Web of Science ®Google Scholar
• Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, Malvini L, Barbui C, Cipriani AM. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst. Rev. 4, CD004185 (2005).
   Google Scholar
• Thase ME. Comparing the efficacy of the newer antidepressants. In: Nuevas Perspectivas en la Depresión, Gilaberte I (Ed.), Aula Médica Endiciones, Madrid, Spain 253–286 (2004).
   Google Scholar
• Heuzenroeder L, Donnelly M, Haby MM et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust. NZ J. Psychiatry 38, 602–612 (2004).
   PubMed Web of Science ®Google Scholar
• Guest JF, Russ J, Lenox-Smith A. Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom. Eur. J. Health Econ. 6(2), 136–145(2006).
   Google Scholar
• Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 23, 155–167 (2005).
   PubMed Web of Science ®Google Scholar
• Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr. Med. Res. Opin. 2, 631–642 (2005).
   Google Scholar
• Thase ME. Comparing the methods used to compare antidepressants. Psychopharmacol. Bull. 36(Suppl .1), 4–17 (2002).
   PubMedGoogle Scholar